In June 2024, multiple state regulators took joint action against Plutus Financial, Inc (Abra) ordering Abra to cease and desist certain operations in the U.S. and reimburse customers of virtual ...
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...
Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America The findings show a global increase ...
The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations. According to the updated results presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results